Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1942272 | 0.78 | LMNA (0.37) | LMNA | |
| SCHEMBL10463987 | 0.77 | LMNA (0.33) | LMNA | |
| SCHEMBL321303 | 0.71 | LMNA (0.32) | LMNA | |
| SCHEMBL22733768 | 0.71 | LMNA (0.43) | LMNA | |
| SCHEMBL9721740 | 0.71 | LMNA (0.43) | LMNA | |
| SCHEMBL10375751 | 0.70 | HTT (0.32) | LMNA | |
| SCHEMBL3229576 | 0.67 | ELANE (0.46) | LMNA | |
| SCHEMBL4833784 | 0.67 | LMNA (0.40) | LMNA | |
| SCHEMBL16174854 | 0.65 | LMNA (0.44) | LMNA | |
| SCHEMBL287441 | 0.65 | LMNA (0.39) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118255966-A | Preparation method of high-temperature-resistant weather-resistant polyurethane | 安徽恒光聚氨酯材料有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-10954231-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2021-03-23 | — | — | US | disclosed |
| US-10233181-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2019-03-19 | — | — | US | disclosed |
| WO-2018102885-A1 | MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2018-06-14 | — | — | WO | disclosed |
| US-9975892-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2018-05-22 | — | — | US | disclosed |
| US-20180105523-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2018-04-19 | — | — | US | disclosed |
| US-20180105524-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2018-04-19 | — | — | US | disclosed |
| US-20170183347-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2017-06-29 | — | — | US | disclosed |
| US-9573945-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2017-02-21 | — | — | US | disclosed |
| EP-2540722-B1 | Novel anxiolytic compounds | BIONOMICS LTD (AU) | 2016-06-08 | — | — | EP | disclosed |
| EP-2540722-A1 | Novel anxiolytic compounds | Bionomics Limited (AU) | 2013-01-02 | — | — | EP | disclosed |
| EP-2074123-B1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LTD (AU) | 2012-12-05 | — | — | EP | disclosed |
| US-8293737-B2 | Anxiolytic compounds | BIONOMICS LIMITED (AU) | 2012-10-23 | — | — | US | disclosed |
| WO-2012116410-A1 | METHODS OF TREATING A DISEASE OR CONDITION OF THE CENTRAL NERVOUS SYSTEM | BIONOMICS LIMITED (AU) | 2012-09-07 | — | — | WO | disclosed |
| US-20100105678-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2010-04-29 | — | — | US | disclosed |
| EP-2074123-A1 | NOVEL ANXIOLYTIC COMPOUNDS | Bionomics Limited (AU) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008046135-A1 | NOVEL ANXIOLYTIC COMPOUNDS | BIONOMICS LIMITED (AU) | 2008-04-24 | — | — | WO | disclosed |
| EP-1177177-B1 | SUBSTITUTED 4-OXO-QUINOLINE-3-CARBOXAMIDES: GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2005-02-23 | — | — | EP | disclosed |
| US-6413956-B1 | AGONISTS, ANTAGONISTS OR INVERSE AGONISTS AND LOCALIZATION PROBES FOR GAMMA AMINOBUTYRIC ACID BRAIN RECEPTORS; ANXIETY, DEPRESSION, DOWN SYNDROME, SLEEP AND SEIZURE DISORDERS, OVERDOSE WITH BENZODIAZEPINE DRUGS AND MEMORY ENHANCEMENT | NEUROGEN CORPORATION | 2002-07-02 | — | — | US | disclosed |
| EP-0270494-A2 | Certain cycloalka- [b]-pyrazolo-[3,4-d]-pyridin-3-one derivatives | CIBA-GEIGY AG (CH) | 1988-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105523-A1 | NOVEL ANXIOLYTIC COMPOUNDS | SLC18A2, CNR1, OPRK1 | LMNA 4030/4885 |
| US-20170183347-A1 | NOVEL ANXIOLYTIC COMPOUNDS | SLC18A2, CNR1, OPRK1 | LMNA 4043/4885 |
| US-10233181-B2 | Anxiolytic compounds | GABBR1, GABRA6, SLC18A2 | LMNA 2761/4885 |
| US-20100105678-A1 | NOVEL ANXIOLYTIC COMPOUNDS | SLC18A2, CNR1, OPRK1 | LMNA 4043/4885 |
| US-20180105524-A1 | NOVEL ANXIOLYTIC COMPOUNDS | SLC18A2, CNR1, OPRK1 | LMNA 4043/4885 |
| US-10954231-B2 | Anxiolytic compounds | GABRA6, GABRA2, GABRA5 | LMNA 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.